Peripheral blood stem cells and progenitor cells, collected during recovery from exposure to cytotoxic agents or after cytokine administration, are being increasingly used in clinical bone marrow transplantation. To determine factors important for mobilization of both primitive stem cells and progenitor cells to the blood, we studied the blood and splenic and marrow compartments of intact and splenectomized mice after administration of recombinant human interleukin-11 (rhlL-111, recombinant rat stem cell factor (rrSCF), and IL-l1 + SCF. IL-l1 administration increased the number of spleen colony-forming units (CFU-S) in both the spleen and blood, but did not increase blood long-term marrow-repopulating ability (LTRA) in intact or splenectomized mice. SCF administration increased the number of CFU-S in C YTOKINES ARE increasingly being used as a means to improve the yield of hematopoietic donor progenitor and stem cells collected from the blood for autologous transplantation. However, little is known of the mechanisms that control the movement of hematopoietic stem cells between the bone marrow (BM) and the blood. The most effective method for mobilizing blood stem and progenitor cells and the quality of long-term engraftment in peripheral blood stem cell (PBSC) recipients needs further study, especially because new cytokines are being introduced into clinical trials.
Similarly, day-8 to -12 spleen colony-forming unit ': :FU-S) numbers are increased up to 90-fold over those of unstimulated blood. In addition, primitive stem cells measured by long-term marrow-repopulating ability (LTRA) are increased in the blood to levels similar to those of the These experiments in mice have provided a means to study mobilization of both progenitor and primitive stem cells, the cell populations responsible, respectively, for providing short-term engraftment and maintaining long-term hematopoiesis in lethally irradiated hosts.
The current experiments were designed to study mobilization of blood primitive stem cells after treatment with IL-I1 administered alone or in combination with SCF in a mouse model. IL-l I is a pleotropic growth factor that has shown activity in a variety of hematopoietic assay systems. IL-l1 enhances IL-3 -dependent proliferation of primitive blast cell colonies in methylcellulose cultures" and synergizes with SCF to enhance the formation of multilineage colonies.Ix IL-1 1 increases megakaryocytic colony formation and colony size from both murine and human BM in the presence of IL-3.'"*' In vivo, IL-l 1 has been shown to elevate platelets in normal mice and to accelerate both neutrophil and platelet recovery in mice when administered daily after irradiation and BM transplantation.2' Finally IL-1 1 combined with SCF has been shown to greatly increase the proliferation and maintenance of nucleated cells, day-7 CAFCs, and day-28 CAFCs (equivalent to long-term repopulating cells [LTRCs] ) in liquid culture when compared with SCF alone."
The current data show that, in contrast to other cytokines. IL-1 1 administration increases the progenitor cell content but not the primitive stem cell content of the blood and spleen. However, IL-I 1 synergizes with SCF to increase the number of blood and splenic LTRCs. In addition, in splenectomized mice, IL-I 1 enhances SCF mobilization of primitive stem cells from the BM to the blood. These data provide further evidence for different cytokine-specific mechanisms of mobilization of progenitor and primitive stem cells.
Stem cell mobilization by IL-l I + SCF administration. Recombinant rat polyethylene glycol (PEG)-treated SCF (rrSCF-PEG) was generously provided by Amgen (Thousand Oaks, CA). rrSCF-PEG is required for in vivo activity because of reported suboptimal results with the unpegylated form." Mice received rhIL-l1 (250 pg/kg/d), rrSCF-PEG (100 pg/kg/d), and rhIL-l1 + rrSCF-PEG (same doses as above) by subcutaneous injection twice daily for 7 days and were compared with saline-treated controls. We chose to use the subcutaneous route when combining IL-I 1 with SCF to simplify administration and because of concerns that the pump might stimulate other in vivo cytokine production through postsurgical and inflammatory mechanisms. The dose and administration of SCF was adopted from Molineux and colleagues.24 Animals were assayed for changes in blood, spleen, and BM cellularity and for CFU-S content and LTRA 3 hours after cessation of cytokine administration. PB, spleen, and BM measurements. PB cell counts were measured on a Coulter counter (Coulter Electronics, Hialeah, FL). Four separate determinations were performed on each sample. PBSCs were then harvested from whole blood by cardiac puncture 15 to 30 minutes after injection of 50 U of heparin. Approximately 1 mL was collected per mouse and was diluted into an equal volume of PBS containing heparin in 15-mL centrifuge tubes and centrifuged through a Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradient to remove erythrocytes. All nucleated cells between the lower erythrocyte fraction and upper serum fraction were collected and washed once with PBS. No attempt was made to separate mononuclear cells from polymorphonuclear cells. Spleens were removed and individually weighed. They were ground in PBS between 2 frosted slides BM was isolated from a femur and tibia by flushing with sterile PBS and breaking the material into a single cell suspension for individual hindlimb counts before pooling for stem cell assays. Stem cell assays. Several different stem cell assays were used. The CFU-S assay" was performed by injecting limited numbers of nucleated BM, spleen, or blood cells into the tail vein of 7 to 8 lethally irradiated recipients (950 cGy, single dose, at 95 cGy/min). Mice were killed 8 days later for spleen colony enumeration.
Long-term competitive repopulation in vivo was used as the measure of primitive stem cell c~n t e n t . '~.~~ The competitive repopulation assay measures the LTRA of a test stem cell population relative to normal BM ~e l l s . '~~*~ For LTRA determination, varying numbers of BM or blood test cells (2 X 10' to 1 X 10') from B6 (Hbb) mice were mixed with a constant number (5 X IO5) of normal control B6-Hbbd BM cells. The mixtures were injected into groups of 5 to 6 lethally irradiated B6-Hbb' recipients (1,250 cGy split-dose total body irradiation, 3 hours apart at 95 cGy/min). Absence of endogenous BM repopulation was determined by injecting one group with control cells only (Hbbd). Recipients were bled from the tail vein 6 months later and ratios of test-(Hbb") to-control (Hbbd) hemoglobin were determined by electrophoresis of PB cell lysates.'" The competitive repopulating index (CRI; a measure of LTRA) was calculated by the formula: CRI = Ratio of test-to-control hemoglobin in recipients of BM mixture + Ratio of test-to-control BM cells transplanted.
RESULTS
Increases in day-8 CFU-S content in the blood and spleen after IL-l1 administration. Nucleated blood counts and day-8 CFU-S content were measured in the blood and spleen at days 3, 7 , 10, 13, and 17 after rhIL-l l administration by either subcutaneous injection or subcutaneous infusion to determine the kinetics and duration of mobilization. None of the WBC/mL determinations for the rhIL-l1 subcutaneous and mini-osmotic pump groups were significantly increased over those of controls. Peak values in blood and spleen CFU-S content were observed at 7 days (3 hours after cessation of IL-l l), with a relative increase in CFU-S for blood and spleen of 3.7-and 13.5-fold, respectively, for subcutaneous administration, and of 7.9-and 42.1-fold, respectively, for Alzet-pump administration (see Table 1 ). Blood and spleen C m -S levels were increased by 3 days and did not return to normal until after 13 days. At 10 days, CFU-S values were still 22% to 68% of day-7 levels (data not shown).
Primitive stem cell content was measured in the blood and BM 7 days after beginning rhIL-l1 administration (3 hours after cessation of IL-11) by 6-month LTRA studies (see Table 2 ). The LTRA of the blood was not increased after IL-11 administration. Similarly, no changes in LTRA were observed in the BM.
Increased cellularity and day-8 CFU-S content in the blood and spleen after SCF alone or after SCF and IL-11. A twofold increase in day-8 CFU-S/mL blood was observed after rhIL-l1 treatment alone compared with that of controls (no increase in WBC/mL). Statistically significant increases in WBC counts (1.5-to 2.0-fold) and in the frequency of day-8 CFU-S (per lo6 blood cells; sevenfold) were noted for animals receiving SCF (P < .001) or SCF + rhIL-l1 (P < ,001) over those of unperturbed control blood (Table 3) . SCF or SCF + rhIL-l1 resulted in an 11-to 14-fold increase in 
Values are mean f SEM. Pvalues, calculated using the Student's t-test, compare experimental data with unperturbed (saline subcutaneous or saline pump, respectively) control blood or spleen cells. No. of individual measurements is shown in parentheses. Measurements represent values from 1 to 4 separate experiments. PB CFU-S determinations were performed on cells from Ficoll-Hypaque gradient separations. The relative increase in CFU-S for mobilized blood was calculated by multiplying WBC x 106/mL by CFU-S frequency/106 blood cells and dividing by the product of the control values. The CFU-WO6 blood cells were significantly increased after IL-l1 administration as compared with that of controls. In contrast, none of the WBC/mL determinations for the IL-l1 subcutaneous and Alzet pump groups were significantly increased over controls. For each splenic CFU-S measurement, a minimum of three spleens were pooled for analysis. The CFU-S contentispleen was determined by multiplying the no. of cells/spleen by the number of CFU-S/106 spleen cells. The relative increase in CFU-S/spleen after cytokine administration is compared with that of control spleen CFU-S measurements.
Abbreviations: SUB Q, subcutaneous; Rel, relative, absolute circulating CFU-S numbers as compared with those of control animals. Significant differences were not observed between SCF and SCF + IL-1 1. These data suggest that IL-1 1 alone or in combination with SCF has only modest effects on blood nucleated cell and CFU-S content. Statistically significant increases in day-8 CFU-S content per spleen were noted for animals receiving IL-1 I ( P < .001), SCF ( P < .001) or SCF + IL-11 ( P < .001) over those of unperturbed control blood (Table 4) . Increases were the largest in mice treated with SCF + IL-I 1 > SCF > XL-1 I . Specifically, there was a 64-fold increase in the CFU-S content of the spleen after SCF + IL-l l as compared with a 37-fold increase after SCF alone and only a 4.5-fold increase after IL-l1 alone, suggesting that IL-1 1 had a synergistic, rather than an additive, effect when combined with SCF on splenic CFU-S content. A corresponding but modest decrease in hindlimb cellularity and C m -S content of the BM was observed after cytokine administration. Control CFU-S per hindlimb values were 6,048 2 605 (n = 9) versus 4,324 f 707 (n = 7, P = NS) after IL-11, versus 4,876 2 482 (n = 4, P = NS) for SCF, and versus 4,044 +-495 (n = 7 , P < .02) for IL-l1 +
SCF.
Primitive stem cell content in the blood, spleen, and BM a f e r IL-l1 alone, SCF alone, or SCF + [L-11. The CRI was determined for BM, spleen, and blood cells. Unstimulated blood was severely deficient in LTRA as compared with normal BM, as has been previously reported in numerous other studies ( in the SCF and IL-11 + SCF groups were significantly increased ( P < ,001) over those of the IL-l1 group.
Abbreviation: NS, not statistically significant.
increase in blood LTRA (CRI = 0.015 to 0.029). Only in the IL-11 + SCF group were the blood values significantly different from unstimulated controls, and, because of the low numerical values, it is doubtful whether this significance represents a real biological effect. Animals treated with IL-11 alone or SCF alone did not show an increase in LTRCs in the spleen; however, the number of LTRCs was increased in SCF + IL-11 mice (Table 5) . These data suggest a synergistic rather than additive effect when IL-11 was combined with SCF. Modest decreases (not statistically significant) were observed in the LTRA of the BM after cytokine administration. Primitive stem cells are increased in the blood after SCF alone or SCF + IL-l1 in splenectomized mice. Similar experiments were performed in splenectomized mice to measure cellularity, CFU-S content, and LTRA in the blood and BM after cytokine administration. Increases in WBC/mL, CFU-S/106 cells, and relative increase in circulating CFU-S were similar to those observed in nonsplenectomized animals ( Table 6 ). IL-1 1 had little impact on WBC counts and CFU-S content of the blood when administered in combination with SCF in splenectomized mice as compared with that of SCF alone. These results were similar to what was observed in mice with intact spleens. BM cellularity and CFU-S content per hindlimb was significantly decreased after cytokine administration. Specifically, control CFU-S per hindlimb values were 7,249 versus 4,587 after IL-11 (P < .001), versus 4,698 after SCF ( P < .001), and versus 5,060 after IL-11 + SCF ( P < .001; see Table 7 ). This decrease in CFU-S content reflected the decrease in cellularity rather than a decrease in the frequency of CFU-S/I06 cells.
Splenectomized animals treated with IL-I 1 alone showed no increase in blood LTRA. However, animals treated with For personal use only. on April 16, 2017. by guest www.bloodjournal.org From SCF alone or SCF + XL-l 1 showed a significant increase in blood primitive stem cell content ( Table 8) . No differences in blood LTRA were observed between SCF and SCF + IL-11. The LTRA of the BM was significantly decreased with SCF + IL-11 but not with the other combinations. This BM effect appeared greater than that in nonsplenectomized animals.
DISCUSSION
The ability of IL-l1 to mobilize blood stem cells and progenitors has not been well studied. In this report, we have evaluated the ability of rhIL-1 1, administered either by miniosmotic pump or by subcutaneous administration, to increase hematopoietic stem cells in PB and spleen. The data show that rhIL-l1 treatment modestly increased circulating day-8 CFU-S (threefold to eightfold) without increasing blood LTRA. There were greater relative increases in splenic cellularity and splenic CFU-S content (13-to 42-fold) after IL-1 1 administration compared with that in the blood; however, there was no increase in splenic LTRA. The inability of IL-11 to increase the LTRA of the blood or spleen was surprising, given that the increases in splenic CFU-S after rhIL-l1 (by Alzet pump) were dramatic. These differential effects on CFU-S and LTRA were not due to suboptimal dosing with IL-11, because since data were collected in mice receiving rhIL-l l both by subcutaneous injection and by subcutaneous infusion. In addition, rhIL-l1 administered subcutaneously to splenectomized mice did not increase blood LTRA. These data suggest that rhIL-l1 may mobilize early hematopoietic progenitor cells to the blood and spleen but has little effect on mobilization of primitive stem cells.
As with rhIL-11, we also examined the ability of rrSCF to mobilize different subpopulations of hematopoietic stem cells to PB and spleen. Similar to IL-1 1, we show that rrSCF administered alone was ineffective in increasing the LTRA of the blood or spleen ( Table 5 ). The increase in blood and splenic progenitors without a corresponding increase in LTRA suggests that, in normal mice, either the blood and splenic CFU-S compartments were directly expanded without mobilization after rhIL-l1 or rrSCF treatment or, alternatively, mobilization of BM CFLJ-S, but not of primitive stem cells, occurred after cytokine treatment. However, in contrast to these results in normal mice, rrSCF was able to increase the LTRA of the blood to normal BM levels in splenectomized mice. This increase suggests alternative mechanisms for mobilization of primitive stem cells in rrSCF-treated splenectomized versus nonsplenectomized mice.
The spleen is a reservoir for circulating stem and progenitor cells. After injection of stem cells into lethally irradiated recipients, the spleen is one of the first organs colonized. This probably occurs, in part, through receptors in the splenic microenvironment that are capable of binding stem and progenitor cells. Evidence that this occurs in unirradiated mice is suggested in the current experiments by the very high relative increase in splenic CFU-S after rhIL-l1 (Alzet pump), SCF, and rhIL-l l + SCF treatment as compared with a lower relative increase in circulating CFU-S. Similarly, high relative splenic versus circulating CFU-S increases have been reported after treatment with CY + G-CSF. ' Konno and colleagues" have proposed different mechanisms for homing of progenitor cells to the spleen and BM. For progenitor cells to bind the BM, they must express homing receptor that recognizes mannosyl and galactosyl specificities on the BM stroma. However, the spleen did not function through binding of homing receptor, which suggests that expression of different surface markers may allow preferential binding to the spleen versus the BM or may allow continued circulation in the blood.
The spleen is also an extramedullary source of hematopoiesis in mice; its function differs from the human spleen under For personal use only. on April 16, 2017. by guest www.bloodjournal.org From steady-state circumstances. The enormous increase in CFU-S in the spleen after cytokine administration suggests the existence of a splenic "reserve" population that is exceptionally responsive to cytokine treatment. This reserve population may be a remnant from fetal development when the spleen was the major site of hematopoiesis, and these progenitors remain for emergency use. Under emergency conditions (either true or experimentally induced) when an overabundance of cytokines is present, thus causing proliferation, the spleen may be the preferential hematopoietic organ because its greater elasticity would allow the optimal expansion of cells.30 Administration of SCF or SCF + IL-l1 to splenectomized mice in our experiments resulted in a greater decrease in BM cellularity and CFU-S content than that in mice with intact spleens. This is consistent with a feedback mechanism by which mice with intact spleens first use the cytokine-stimulated splenic reserve population, thus requiring less proliferation or mobilization from the BM. However, in the event that the spleen is missing, the animal must resort to use of the BM stem cells, thus requiring greater proliferation and/or exit from the BM.
There is strong evidence from the current study that rhIL-11 synergistically enhanced SCF release of primitive stem cells from the BM to the blood and spleen. rhIL-1 1 synergistically enhanced both the CFU-S content and LTRA of the spleen when added to SCF (Tables 4 and 5) , and, in splenectomized mice, IL-11 + SCF administration was associated with a significant decrease in BM LTRA ( Table 8 ). There is also evidence for synergy between SCF and G-CSF. In splenectomized mice, rrSCF (high-dose) and rrSCF (lowdose) in combination with rhG-CSF mobilized PBSCs that improved 60-day survival of lethally irradiated mice as compared with that of carrier-mobilized PBSCs.'" In these studies, rrSCF-PEG and G-CSF appeared to act synergistically.
We have previously reported dramatic increases in blood LTRA after CY, G-CSF, and CY + G-CSF treatment to near normal BM levels in mice with intact spleens3; in contrast, we saw only minimal or no increases in the LTRA of the blood of mice with intact spleens exposed to SCF or SCF (mobilization observed in splenectomized mice). These differences may be due to differences in receptor expression or interaction between multiple receptors on various hematopoietic populations." Although it is not known whether the mechanisms that govern the release of stem and progenitor cells from the BM into the blood are the same as those that direct the homing of transplanted stem cells, a number of different cytokines are known to upregulate or downregulate specific adhesion molecules on both progenitor cells and endothelium and may mediate both the binding and release of hematopoietic stem and progenitor c-kit is expressed on both progenitor and more primitive stem ~e l l s .~~.~~ Recent data in mice suggest that IL-3 and GM-CSF may downregulate kit.^' Another study showed downregulation of c-kit on M-07e cells by macrophage growth factor and granulocyte-macrophage CSF but not by IL-3, IL-2, IL-4, IL-6, and IL-9.38 In our laboratory, pretreatment of BM with IL-l and SCF followed by stem cell purification with sedimentation and negative selection techniques resulted in an unexpectedly low expression of c-kit. The deficiency in steel mice and the presence of a separate membrane-bound form of SCF on hematopoietic stroma suggest that this ligandreceptor relationship may be a crucial modulator of hematopoietic stromdstem cell interaction. However, the current study still proposes that multiple receptors are involved. SCF may downregulate c-kit and allow its release from the BM, but a second receptor results in its being competitively bound to the spleen. IL-I 1 enhances the SCF-mediated release of LTRCs but does not affect their binding to the spleen. G-CSF may downregulate both BM and splenic receptors.
blood and progenitor cells that have enhanced repopulating potential. Blood 82:1720, 1993
